Boulder, Colorado (PRWEB) October 27, 2013
QI Path, a Boulder-based risk management firm, will introduce Enterprise Genomics™ - a patented new model for prospective enterprise risk management – at the American Society for Healthcare Risk Management (ASHRM) annual conference in Austin, Texas this week.
Enterprise Genomics™ utilizes patented data models to transform risk management from reactive to proactive, allowing clients to identify and mitigate risks before they produce negative outcomes.
According to John Roemer, the company’s COO, the solution "accounts for the systemic failure of traditional reactive risk management models, which rely too heavily on post-incident analysis. That analysis is difficult to do in hospitals, where the number of overlapping processes involved in even the ‘simplest’ procedure is very large, and where the pace of activity makes it difficult to retrace steps. With Enterprise Genomics™, hospitals will be able to untangle their complex webs of processes and visualize prospective risks with absolute clarity. That will empower executives, mitigate adverse events, and lower liability costs."
The company cites a report from the VA National Center for Patient Safety, which noted that, "historically, accident prevention has not been a primary focus of hospital medicine," that there has been a "misguided reliance on ‘faultless’ performance by healthcare professionals," and that "hospital systems were not designed to prevent or absorb errors," but "just reactively changed and were not typically proactive."
According to Kurt Rinehart, VP of Analytics, the problems in health care risk management are compounded by the particular realities the sector faces: "While other industries are able to manipulate risk exposure through acceptance, sharing, avoidance, reduction, or alternative actions, the medical industry cannot engage all of those methods. Acceptance, avoidance, or sharing of risk is often unacceptable in environments where the potential cost of that risk is the loss of human life. That’s what makes a predictive model like Enterprise Genomics™ particularly useful in health care."
In a letter to ASHRM conference attendees, QI Path President Tom Leifer wrote: "A recent study published in the Journal of Patient Safety suggests that medical errors are now the third leading cause of death in the United States. At QI Path, we believe that meeting this challenge will require us to fundamentally reshape the traditional approach to medical risk: To transition from looking at what went wrong yesterday to accurately predicting what will go wrong tomorrow."
The company believes that the potential of Enterprise Genomics™ mirrors that of human genomics, and that – by discovering what negative incidents enterprises are predisposed to – they can help executives take preventive action. Mr. Roemer says, "once you identify a that a human being has a genetic predisposition to a particular disease, you can act on that information and take measures to reduce their chances of getting sick. The same principle applies to Enterprise Genomics™."
That doesn’t mean that Enterprise Genomics™ ignores data gathered through traditional risk management practices, however. According to Dr. Laura Kohlhagen MD MBA, VP of Provider Solutions, "The Enterprise Genome™ has two strands – one coded with retrospective data and the other with prospective data – and together they give us a comprehensive view of enterprise risk. We’re certainly not dismissing the value of reactive risk analysis. We’re making that information actionable by adding a predictive element that employs the power of ‘big data’ where it can make the most difference: In preventing medical errors and saving lives."
The solution will be introduced beginning on Sunday, October 27th at the ASHRM annual conference, and members of the QI Path team will be on hand to explain the product to conference attendees. Mr. Leifer explains: "We’re proud to introduce this at ASHRM – an annual gathering of the people on the front lines of the battle against medical risk. We’re here to empower them with an innovative solution that will make their jobs easier, and to figure out what else we can do to help them achieve their goals." After all, he says, "We all know that the future holds millions of new patients who will require high quality medical care at lower cost, and we are absolutely confident that Enterprise Genomics™ – and the transition from reactive to proactive risk management it represents – is fundamental to meeting that challenge."